HOW IS NASH TREATED?

There are still no approved therapies indicated for NASH patients.¹ But that’s about to change. Regulatory authorities and the scientific community have accelerated clinical trials and approval procedures for NASH, with the goal of providing patients with NASH access to approved therapy as soon as possible.²

Today, diet, lifestyle modification, and exercise remain the top priorities and recommendations for patients. The ultimate goal is to achieve and sustain weight loss of 7% to 10% of bodyweight, as this has been shown to improve most histopathological features of NASH.³

The Liver Forum provides an independent and neutral venue for experts across disciplines and stakeholders, including regulators, patients, industry, and academia representatives, to share information and insight and collaborate to advance the regulatory science for treatment. Visit the forum to learn how NASH treatment is advancing in real time.

HOW IS NASH MANAGED

EXPLORE OUR EDUCATIONAL BROCHURES

References

1. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016;64(6):1388-1402.
2. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362-376.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023.